References
- Hedger MP, Winnall WR, Phillips DJ, et al. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm. 2011;85:255–297.
- Oshima T, Yoshihara K, Aoyama T, et al. Relation of INHBA gene expression to outcomes in gastric cancer after curative surgery. Anticancer Res. 2014;34:2303–2309.
- Wang Q, Wen YG, Li DP, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29:77–83.
- Lee HY, Li CC, Huang CN, et al. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol. 2015;111:414–422.
- Togashi Y, Sakamoto H, Hayashi H, et al. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Mol Cancer. 2014;13:126.
- Togashi Y, Kogita A, Sakamoto H, et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 2015;356:819–827.
- Huang YW, Lee WH, Tsai YH, et al. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. Am J Physiol Cell Physiol. 2014;306:C37–C44.
- Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA. 2010;107:5124–5129.
- Silbermann R, Bolzoni M, Storti P, et al. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014;28:951–954.
- Zhang Y, Qi Y, Zhao Y, et al. Activin A induces apoptosis of mouse myeloma cells via the mitochondrial pathway. Oncol Lett. 2018;15:2590–2594.
- Si T, Lu Y, Li F, et al. High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. Leuk Lymphoma. 2018;59:114–120.
- Jiang L, Si T, Yu M, et al. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59:1202–1212.
- Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.